Prenatal and Newborn Genetic Testing Market Size, Trends and Growth Analysis by 2027

The global market for Prenatal and Newborn Genetic Testing is projected to grow significantly, reaching approximately US$ 11,204.74 million by 2027, up from US$ 4,034.37 million in 2018. This growth represents a compound annual growth rate (CAGR) of 12.2% from 2019 to 2027.

Several factors are contributing to this robust growth, including the rising incidence of genetic disorders in infants, government initiatives that encourage the adoption of prenatal and newborn testing, and an increasing birth rate. Furthermore, the potential for growth in emerging markets within developing nations is expected to positively influence the market's expansion in the years ahead.

Genetic disorders can affect fetuses during pregnancy, and the inheritance patterns of these conditions play a crucial role in assessing the risks they pose to both the pregnancy and the likelihood of recurrence in future pregnancies. The risk of genetic disorders in newborns is heightened when parents have previously had a child with a genetic condition, have a family history of such disorders, or if one of the parents has a chromosomal abnormality. The prevalence of genetic disorders in infants is notably high, and these conditions are a significant contributor to infant mortality worldwide. For example, the World Health Organization reported in 2016 that around 7.9 million infants globally are born with genetic defects. Additionally, the Centers for Disease Control and Prevention (CDC) indicates that birth defects affect approximately 1 in 33 infants born in the United States. Chromosomal abnormalities, such as Down syndrome, are reported to affect 1 in 691 births in the US, according to CDC data from 2017. Consequently, the high incidence of genetic disorders among infants is driving the demand for prenatal and newborn genetic testing, thereby fostering market growth.

The global Prenatal and Newborn Genetic Testing Market is categorized based on product type, disease indication, and end user. The product category is further divided into diagnostic tests and screening tests. In terms of disease indication, the market includes conditions such as cystic fibrosis, sickle cell anemia, Down syndrome, phenylketonuria, among others. Regarding end users, the market is segmented into hospitals and clinics, diagnostic centers, and other healthcare providers. Hospitals and clinics dominate the end user segment, as they serve as the primary healthcare facilities for patients seeking these tests.

The report on the Prenatal and Newborn Genetic Testing Market incorporates a variety of primary and secondary sources, including reputable organizations such as the World Health Organization, the UAE Genetic Diseases Association, the Centre for Arab Genomic Studies, the National Health Service (NHS), the Centers for Disease Control and Prevention, the National Human Genome Research Institute (US), and the Florida Department of Health, among others.